Keros Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that its board of directors approved a new stock repurchase program of up to $5 million following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc.

Key Highlights

  • Repurchase program size: The board approved a new stock repurchase program for up to $5 million of the company's common stock.
  • Milestone trigger: The repurchase followed receipt of a $20 million development milestone payment under the license agreement with Takeda Pharmaceuticals U.S.A., Inc. in November 2026.
  • Cash position: As of September 30, 2026, the company reported cash and cash equivalents of $259.5 million.
  • Runway projection: The company anticipates its cash, after accounting for the $20 million Takeda milestone and the stock repurchase, will be sufficient to fund operating expenses and capital expenditure requirements into 2029.
  • Announcement date: The board approval and press release were both dated November 16, 2026.

Keros Therapeutics Discloses Repurchase Program Funded by Takeda Milestone Payment

According to the filing, Keros Therapeutics (NASDAQ:KROS) announced on November 16, 2026 that its board of directors approved a new stock repurchase program authorizing the repurchase of up to $5 million of the company's common stock. The company disclosed that the program follows receipt of a $20 million development milestone payment under its license agreement with Takeda Pharmaceuticals U.S.A., Inc., which was received in November 2026.

The company reported cash and cash equivalents of $259.5 million as of September 30, 2026. The filing states that, based on its current operating plans, the company anticipates that its cash position, after giving effect to both the $20 million Takeda milestone payment and the stock repurchase program, "will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2029."

The 8-K was signed by Jasbir Seehra, Ph.D., Chief Executive Officer of Keros Therapeutics, Inc. The filing includes as Exhibit 99.1 a press release dated November 16, 2026, which is incorporated by reference into the report. The company is incorporated in Delaware and lists its principal executive offices in Lexington, Massachusetts.

What Was Disclosed

Keros Therapeutics filed an 8-K reporting board approval of a $5 million stock repurchase program, funded in connection with a $20 million development milestone payment from Takeda received in November 2026, and provided a cash runway statement extending into 2029.